Ionis Pharmaceuticals, Inc. Common Stock: tracked funds

IONSfinancial statementsinsider trading

Across each manager’s latest 13F filing, mostly for Q3 2026, 1 of the 18 tracked managers held Ionis Pharmaceuticals, Inc. Common Stock; none opened a position, none added, 1 trimmed, 1 sold out. Largest: Renaissance Technologies at 0.0% of its portfolio.

Funds holding it
1
of 18, each on its latest filing
Opened or added
0
0 opened, 0 added
Trimmed or sold out
2
1 trimmed, 1 sold out
Largest weight
0.0%
Renaissance Technologies; combined $16M

Filings through November 16, 2026. Each fund is measured on its own latest 13F; counted in funds, not dollars.

The trend

Q4 2023 to Q3 2026, each fund in the quarter its filing covers, so the newest quarter can trail the figures above while filings come in.

Tracked funds holding it, and what they did, by quarterholders funds that had filed
018Q4 2023: 1 of 17 funds that had filed held itQ1 2024: 1 of 18 funds that had filed held itQ2 2024: 1 of 18 funds that had filed held itQ3 2024: 1 of 18 funds that had filed held itQ4 2024: 1 of 18 funds that had filed held itQ1 2025: 1 of 18 funds that had filed held itQ2 2025: 1 of 18 funds that had filed held itQ3 2025: 2 of 18 funds that had filed held itQ4 2025: 2 of 18 funds that had filed held itQ1 2026: 2 of 18 funds that had filed held itQ2 2026: 2 of 18 funds that had filed held itQ3 2026: 1 of 10 funds that had filed held it22Q1'24Q3'24Q1 2025: 1 trimmed, 0 sold outQ1'25Q2 2025: 0 opened, 1 addedQ3 2025: 1 opened, 1 addedQ3'25Q4 2025: 0 opened, 1 addedQ4 2025: 1 trimmed, 0 sold outQ1 2026: 0 opened, 2 addedQ1'26Q2 2026: 0 opened, 1 addedQ2 2026: 1 trimmed, 0 sold outQ3 2026: 1 trimmed, 1 sold outQ3'26

Each fund is placed in the quarter of its own filing. Above the lower line, funds that opened or added more than 1% of their shares; below, funds that trimmed more than 1% or sold out.

The funds

Every tracked fund with a position in its latest filing, largest weight first, and those that sold out. Bars show shares at each quarter end: green when it added, red when it sold.

FundManagerQuarterWeight× averageValueSharesChangeMoveShares by quarter
Renaissance TechnologiesPeter BrownQ3 20260.02%0.7×$16M354,214−36.7%trimmed2023-12-31: 112,414 shares, 0.0%2024-03-31: 179,714 shares, 0.0%2024-06-30: 249,514 shares, 0.0%2024-09-30: 190,514 shares, 0.0%2024-12-31: 205,514 shares, 0.0%2025-03-31: 153,514 shares, 0.0%2025-06-30: 270,714 shares, 0.0%2025-09-30: 486,714 shares, 0.0%2025-12-31: 223,607 shares, 0.0%2026-03-31: 305,549 shares, 0.0%2026-06-30: 559,414 shares, 0.1%2026-09-30: 354,214 shares, 0.0%
Baron Capital GroupRon BaronQ3 20260%—$00—sold out2025-09-30: 25,000 shares, 0.0%2025-12-31: 36,000 shares, 0.0%2026-03-31: 45,000 shares, 0.0%2026-06-30: 14,000 shares, 0.0%

Questions

Which hedge funds own IONS?

Across each manager's latest 13F filing (mostly Q3 2026), 1 of the 18 tracked managers held Ionis Pharmaceuticals, Inc. Common Stock: Renaissance Technologies (under 0.1%).

Did Renaissance Technologies add or sell IONS last quarter?

In its Q3 2026 13F, filed November 12, 2026, Renaissance Technologies trimmed its position, shares 37% lower; IONS was 0.0% of its reported portfolio.

What is a 13F and what does it miss?

Managers with $100 million or more in US equities report their long positions on Form 13F each quarter, up to 45 days after it ends. The filing omits short positions, bonds, cash and most foreign listings, and a position may have changed since the quarter ended. Options are excluded here.

From the managers’ Form 13F-HR filings with the SEC, amendments applied, share counts adjusted for splits; GOOG and GOOGL are one position. A record of filings, not a recommendation.